Prof. PeptideProf. Peptide
Guide

How is BPC-157 dosed?

BPC-157 has no approved product anywhere and essentially no completed controlled human trial. This page reports what actually exists — three small published human pilot studies, two registered trials, a large animal literature, and where widely-repeated community dosing diverges from all of it — graded and attributed, never converted into a recommendation.

Topic: Reading BPC-157’s actual evidence base directly, human pilot by human pilot and animal study by animal study

Audience: Anyone comparing a BPC-157 dose figure against what has and hasn’t actually been studied

Reading time: 10–12 minutes

No approved product anywhere, no completed controlled human trial

BPC-157 has not been approved by the FDA, EMA, or any regulatory body in any country. FDA’s own July 2026 evaluation states there is no approved product containing it anywhere and no pharmacopeial monograph for it. What exists instead: three small, uncontrolled human pilot studies; one registered trial with an unknown, unreported status since 2015; one currently recruiting Phase 2 trial; and a substantial animal literature. Every figure below names which of those it comes from.

On this page
  1. 1.What BPC-157 is, and what's actually been tested
  2. 2.The human evidence: three pilots, two registered trials
  3. 3.The animal evidence, reported as animal doses
  4. 4.Community practice, and where it diverges
  5. 5.Regulatory position: Category 2, the PCAC vote, and a warning letter
  6. 6.Related pages
  7. 7.FAQ
  8. 8.References

What BPC-157 is, and what’s actually been tested

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide first described in the literature by Predrag Sikiric’s group in Croatia in 1993, as a fragment derived from a protein in human gastric juice. It has no approved product anywhere, has not completed a controlled human trial, and has no pharmacopeial monograph. The BPC-157 profile covers the proposed mechanism and broader research context; this page exists specifically to read every human and animal dosing study directly, in the order the evidence actually supports.

The evidence below is ordered deliberately: human studies first, graded by design (a registered randomized trial ranks above an uncontrolled retrospective pilot); then animal studies, always labeled as animal doses and never converted into a human figure; then community-reported practice, last, attributed to where it’s found, and marked as unverified — because that is the order the site’s own evidence convention places observed, unstudied practice in.

The human evidence: three pilots, two registered trials

Three human pilot studies have been published, all from the same Orlando, FL physician’s practice, all open-label or retrospective, none randomized, controlled, or blinded. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when it resolves to a named, checkable source — and the design tier is stated explicitly, since none of the three is a controlled trial.

Lee & Padgett 2021 — Knee Pain (Retrospective)

Lee E, Padgett B. Altern Ther Health Med. 2021;27(4):8–13.

Design: Retrospective chart review at the Institute for Hormonal Balance, Orlando, FL, of patients who received an intra-articular BPC-157 injection for knee pain between 2019 and 2020. Uncontrolled, unblinded, no placebo arm; follow-up by phone survey 6 months to 1 year after injection.

Participants: 17 patients received an injection; 16 were reached for follow-up (1 lost to follow-up). Average age 60 (range 19–77); 9 women, 7 men.

Dose administered: 12 patients received BPC-157 alone: 4 mg (2 mL of a 2000 mcg/mL compounded solution) as a single intra-articular knee injection. 4 patients received BPC-157 (2–4 mg) combined with thymosin beta-4 (3–6 mg). BPC-157 was compounded by Tailor Made Compounding LLC, Nicholasville, KY.

Result reported: 11 of 12 (91.6%) improved with BPC-157 alone; 3 of 4 (75%) improved with the combination; 14 of 16 (87.5%) overall. Of the BPC-157-alone group, 7 of 12 (58.3%) reported relief lasting 6 months to 1 year.

Adverse events reported: "Well tolerated with no adverse events noted" across all 16 patients, per the study's own text.

Attributed — read in full from the primary source (institute's own hosted PDF). Uncontrolled, retrospective, unblinded, no placebo arm: this is the design tier below a randomized trial, not a substitute for one.

Lee, Walker & Ayadi 2024 — Interstitial Cystitis (Open-Label Pilot)

Lee E, Walker C, Ayadi B. Altern Ther Health Med. 2024;30(10):12–17. PMID 39325560.

Design: Prospective open-label pilot at a private clinic, in women with moderate-to-severe interstitial cystitis who had not responded to pentosan polysulfate (the only FDA-approved treatment for the condition). Uncontrolled, unblinded, no placebo arm, single procedure per patient.

Participants: 12 women, ages 39–76 (mean 58.3); 10 White, 1 Asian, 1 Latina.

Dose administered: 10 mg total, injected intravesically as 1 mg at each of 10 sites around the area of bladder-wall inflammation, in a single cystoscopic procedure.

Result reported: Complete symptom resolution (self-rated 100% success) in 10 of 12 patients; the remaining 2 rated 80% success (most symptoms resolved, about 20% lingering). No dropouts. All 12 scored 5/5 on the Global Response Assessment.

Adverse events reported: "No adverse events were reported" per the study's own text.

Attributed — verbatim PubMed abstract read directly. Uncontrolled, open-label, no placebo arm, single-procedure design.

Lee & Burgess 2025 — Intravenous Safety Pilot

Lee E, Burgess K. Altern Ther Health Med. 2025;31(5):20–24. PMID 40131143.

Design: IRB-approved open-label safety pilot at a private Florida clinic. Safety-only endpoint (blood work and vital signs); no efficacy measure. No placebo arm.

Participants: 2 patients: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received IV BPC-157 before this trial.

Dose administered: Day 1: 10 mg in 250 mL normal saline, infused over 1 hour. Day 2: 20 mg in 250 mL normal saline, infused over 1 hour. Fasting blood work and vital signs were taken before and after each infusion.

Result reported: No measurable effect on cardiac, hepatic, renal, thyroid, or blood-glucose biomarkers at either dose.

Adverse events reported: "No side effects reported" at either the 10 mg or 20 mg IV dose, per the study's own text.

Attributed — verbatim PubMed abstract read directly. Two-patient, open-label, safety-only pilot: the smallest and least generalizable of the three human studies.

Two trials are registered on ClinicalTrials.gov. Neither has produced published efficacy or safety results as of this page’s build:

NCT02637284 — Phase 1, Oral, Safety/PK

Status: UNKNOWN (per the registry's own status field, unchanged since approximately 2015; no results posted)

Design: Single-center Phase 1 safety and pharmacokinetics trial at Hospital Angeles, Tijuana, in healthy volunteers ages 18–35, registered 2015.

Arms: 42 participants planned, across ascending single-dose cohorts of 1, 3, or 6 oral 1 mg BPC-157 tablets (each cohort with a small placebo control group), plus a 2-week multiple-dose arm of 3 tablets every 8 hours.

Some secondary sources describe this trial as "cancelled"; the registry itself states only that its status is UNKNOWN, which this page reports rather than adopting the stronger secondary characterization.

NCT07437547 — Phase 2, Acute Hamstring Strain

Status: RECRUITING (confirmed against the live ClinicalTrials.gov API on the date this page was built)

Design: Phase 2 randomized trial testing BPC-157 for acute hamstring muscle strain repair, actual start date February 2, 2026.

Arms: 120 participants planned (estimated enrollment).

The only currently active, enrolling human trial of BPC-157 found for this page.

The animal evidence, reported as animal doses

Every figure below is a dose given to an animal in a specific study. Prof. Peptide does not convert an animal dose into a human-equivalent figure by allometric scaling or any other method — a rat given 10 micrograms per kilogram is not evidence for what a human dose should be, and this page does not treat it as such.

Achilles tendon-to-bone healing

Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. J Orthop Res. 2006;24(5):982–989.

Species: Rat

Dose: 10 microgram, 10 nanogram, or 10 picogram per kg body weight, intraperitoneal, once daily

Route: Intraperitoneal

Duration: Daily from 30 minutes post-surgery to 24 hours before analysis; assessed at days 1, 4, 7, 10, 14, and 21 after surgical Achilles detachment

Finding: Improved functional, biomechanical, and histological Achilles tendon-to-bone healing at all three doses tested, versus saline control; also opposed the healing-impairing effect of co-administered corticosteroid.

Medial collateral ligament healing

Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. J Orthop Res. 2010;28(9):1155–1161.

Species: Rat

Dose: Intraperitoneal: 10 microgram or 10 nanogram per kg. Topical: 1.0 microgram per gram of cream. Oral: 0.16 microgram/mL in drinking water (approximately 12 mL/day per rat).

Route: Intraperitoneal, topical, and per-oral (three separate arms)

Duration: Daily, from 30 minutes post-surgery to 24 hours before sacrifice, over a 90-day observation period after surgical ligament transection

Finding: Improved ligament healing (functional, biomechanical, macroscopic, and histological) across all three administration routes tested.

Quadriceps muscle transection

Staresinic M, Petrovic I, Novinscak T, et al. J Orthop Res. 2006;24(5):1109–1117.

Species: Rat

Dose: 10 microgram, 10 nanogram, or 10 picogram per kg body weight, intraperitoneal, once daily

Route: Intraperitoneal

Duration: Daily from 30 minutes post-transection to 24 hours before sacrifice, over a 72-day observation period

Finding: Improved biomechanical and functional healing of completely transected quadriceps muscle, a defect the paper states cannot otherwise be compensated for in rats.

Achilles tendon transection

Staresinic M, Sebecic B, Patrlj L, et al. J Orthop Res. 2003;21(6):976–983.

Species: Rat

Dose: 10 microgram, 10 nanogram, or 10 picogram per kg body weight, intraperitoneal, once daily

Route: Intraperitoneal

Duration: Daily from 30 minutes post-transection to 24 hours before autopsy; assessed at days 1, 4, 7, 10, and 14

Finding: Accelerated healing of a fully transected Achilles tendon versus saline-treated controls, which the paper describes as severely compromised without treatment.

Preclinical multi-species toxicology

Xu C, Sun L, Ren F, et al. Regul Toxicol Pharmacol. 2020;114:104665. PMID 32334036.

Species: Mice, rats, rabbits, and dogs

Dose: Single-dose and repeated-dose toxicity studies; the one adverse finding reported was in dogs at 2 mg/kg in repeated dosing.

Route: Not specified in the abstract by route for each species/study arm

Duration: Single-dose and repeated-dose designs; the affected dogs recovered spontaneously after 2 weeks off the compound

Finding: No serious toxicity in any of the four species. The only reported adverse finding was decreased creatinine in dogs at 2 mg/kg (not at lower doses), which resolved after a 2-week washout. Mild local irritation on a tolerance test; no genetic or embryo-fetal toxicity reported.

Community practice, and where it diverges

Vendor and blog pages describing a “BPC-157 dosing protocol” are plentiful and largely consistent with each other on one figure: 250–500 mcg once or twice daily, commonly on a 5-days-on/2-days-off or multi-week cycle. This is reported here, below the human and animal evidence above, because it is observed practice attributed to where it circulates — not a studied dose. Prof. Peptide has not independently verified it.

It diverges plainly from the human pilot studies above: the community figure is measured in micrograms and repeated over weeks, while all three published human pilots used single or short-course injections measured in milligrams — 4 mg intra-articularly (knee pilot), 10 mg intravesically (cystitis pilot), and up to 20 mg intravenously (safety pilot) — a different order of magnitude and a different administration pattern entirely. No source was found reconciling the two, or explaining how the community figure was derived from either the human pilots or the animal literature’s microgram-to-picogram-per-kg range.

Regulatory position: Category 2, the PCAC vote, and a warning letter

FDA’s own current position weighs against compounding eligibility; a committee vote non-bindingly recommends the opposite.

FDA placed BPC-157 in Category 2 of its 503A bulk-substance evaluation (“significant safety concerns”) on September 29, 2023, citing immunogenicity risk and peptide-related impurity and characterization concerns. The original nominations were later withdrawn, and FDA removed BPC-157 from Category 2 on that procedural basis around April 2026 — not a safety clearance. Checked directly against FDA’s own July 2026 Pharmacy Compounding Advisory Committee (PCAC) briefing document: FDA’s staff evaluation concludes that “a balancing of the criteria weighs against BPC-157 (free base) and BPC-157 acetate being placed” on the 503A Bulks List, citing the absence of a USP/NF monograph, the absence of any approved product containing it in any country, unresolved characterization issues (inconsistent naming, missing purity/impurity data), and immunogenicity concerns for injectable use.

At the PCAC’s public meeting on July 23–24, 2026, the committee voted 8-6 (one abstention) in favor of adding BPC-157 to the 503A Bulks List — against FDA staff’s own recommendation. That vote count is reported here from convergent press coverage of the public meeting (multiple outlets report the identical 8-6-1 figure); the FDA’s own vote-tally document did not extract as readable text in this environment, so the count is attributed to that reporting rather than presented as read directly from an FDA record. The vote is non-binding; FDA had not acted on it as of this page’s build.

A specific FDA warning letter does name BPC-157: on April 1, 2020, FDA sent a warning letter (594743) to Tailor Made Compounding LLC of Nicholasville, KY, stating the firm “compounded drug products using” several unapproved substances “including…BPC 157,” none of which qualified for the 503A exemption. This is the same compounding pharmacy that supplied the BPC-157 used in the Lee & Padgett 2021 knee-pain pilot study above — the letter predates that study’s publication by over a year.

Research-grade BPC-157, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither an approved product nor a lawfully 503A-compounded one under the current, unresolved regulatory position above. It is sold labeled for laboratory research use, not for human administration, and it is not dispensed against a prescription.

FAQ

Is there an FDA-approved BPC-157 product?
No. BPC-157 has not been approved by the FDA, EMA, or any regulatory body in any country, for any indication. FDA's own July 2026 evaluation states there is no approved product containing BPC-157 anywhere, and no USP, NF, European, Japanese, or International Pharmacopeia monograph for it.
Has BPC-157 been tested in a controlled human trial?
Not a completed one. Two trials are registered on ClinicalTrials.gov: NCT02637284 (Phase 1, oral tablets, Hospital Angeles Tijuana, registered 2015) has carried an UNKNOWN status on the registry itself since around 2015, with no results ever posted. NCT07437547 (Phase 2, acute hamstring strain, N=120 planned) is currently RECRUITING, confirmed against the live registry. Three small published human pilot studies exist — a retrospective chart review and two prospective open-label pilots — but none is randomized, controlled, or blinded.
What doses did the human pilot studies use?
Lee & Padgett 2021 injected 4 mg of BPC-157 intra-articularly into the knee (2 mL of a 2000 mcg/mL compounded solution) in 12 patients, and lower combination doses (2–4 mg BPC-157 with thymosin beta-4) in 4 more. Lee, Walker & Ayadi 2024 injected a total of 10 mg intravesically (1 mg at each of 10 sites in the bladder wall) in 12 patients with interstitial cystitis. Lee & Burgess 2025 infused up to 20 mg intravenously over one hour in 2 patients, as a safety pilot with no efficacy endpoint. These are the doses each study administered — not a recommended schedule.
What doses have been studied in animals?
Overwhelmingly rat studies, overwhelmingly intraperitoneal, at doses far smaller than the human pilot studies' injected amounts — commonly 10 microgram, 10 nanogram, or 10 picogram per kilogram body weight, once daily. These are animal doses from specific published studies, reported as such below; Prof. Peptide does not convert them into a human-equivalent figure by any scaling method.
Is there a commonly reported BPC-157 dosing protocol?
Yes — widely repeated across vendor and blog pages, typically 250–500 mcg once or twice daily, often on a 5-days-on/2-days-off or multi-week cycle. This sits below the human pilot and animal evidence in the order this page presents information, because it is reported practice, not a studied dose: it does not match any dose used in the three published human pilots (which used single or short-course injections of several milligrams, not micrograms) or in the registered trials. See the community-practice section for how these compare.
What adverse events have been reported?
In the human pilots: none. Lee & Padgett 2021 reported the injection "was well tolerated with no adverse events noted" across 16 patients; Lee, Walker & Ayadi 2024 reported no adverse events and no dropouts across 12 patients; Lee & Burgess 2025 reported no measurable effect on cardiac, hepatic, renal, thyroid, or glucose biomarkers and no side effects in 2 patients receiving up to 20 mg IV. In animal toxicology (Xu et al. 2020, mice/rats/rabbits/dogs), the only adverse finding was a decreased creatinine level in dogs at 2 mg/kg in repeated dosing, which resolved spontaneously after 2 weeks off the compound; no serious toxicity was reported at any dose in any of the four species tested. None of this is long-term human safety data — the longest human pilot follow-up was roughly a year, in 16 and 12 patients respectively.
What is BPC-157's current FDA compounding status?
In flux, and not yet resolved. FDA placed BPC-157 in Category 2 of its 503A bulks evaluation (“significant safety concerns”) in 2023, then removed it from Category 2 in April 2026 after the original nominations were withdrawn — a procedural step, not a safety clearance. FDA's own July 2026 staff evaluation then concluded the evidence “weighs against” adding BPC-157 to the 503A Bulks List. The Pharmacy Compounding Advisory Committee's July 23–24, 2026 public meeting voted 8-6 (one abstention) in favor of listing it anyway — a non-binding recommendation FDA has not yet acted on. Compounding BPC-157 under 503A is not currently lawful on the basis of that vote alone.

References

  1. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8–13. https://instituteofhormonalbalance.com/wp-content/uploads/2022/02/Intra-Articular-Injection-of-BPC-157-for-Multiple-Types-of-Knee-Pain.pdf
  2. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12–17. PMID 39325560. https://pubmed.ncbi.nlm.nih.gov/39325560/
  3. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20–24. PMID 40131143. https://pubmed.ncbi.nlm.nih.gov/40131143/
  4. ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial, NCT02637284. https://clinicaltrials.gov/study/NCT02637284
  5. ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair, NCT07437547. https://clinicaltrials.gov/study/NCT07437547
  6. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):982–989. PMID 16583442. https://pubmed.ncbi.nlm.nih.gov/16583442/
  7. Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155–1161. PMID 20225319. https://pubmed.ncbi.nlm.nih.gov/20225319/
  8. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109–1117. PMID 16609979. https://pubmed.ncbi.nlm.nih.gov/16609979/
  9. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PMID 14554208. https://pubmed.ncbi.nlm.nih.gov/14554208/
  10. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID 32334036. https://pubmed.ncbi.nlm.nih.gov/32334036/
  11. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 — Evaluation of BPC-157 Related Bulk Drug Substances. https://www.fda.gov/media/193343/download
  12. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  13. U.S. Food and Drug Administration. Warning Letter: Tailor Made Compounding LLC, reference 594743, 2020-04-01. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020

We may earn commissions from peptide vendor affiliate links.